CDK2 and cancer: Furthermore, various cancer types showed dysregulations in CDK2 and/or its cyclin cognates such as breast cancer, endometrial, ovarian, thyroid, lung, hepatocellular carcinomas, melanoma, lymphoma, osteosarcoma, prostate, colorectal, pancreatic cancers, neuroblastoma, and BRCA deficient cancers.20–31